News Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-18 pm EDT			5-day change	1st Jan Change
2.62 ^USD	+3.97%		-3.32%	-17.61%

Mar. 07	Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 07	Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings	Apr. 18	GL
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042	Mar. 20	GL
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024	Mar. 07
Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M	Mar. 07	MT
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update	Mar. 07	GL
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	Feb. 26	GL
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	Feb. 26	AQ
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	Feb. 05	GL
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	Feb. 05	AQ
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	Jan. 04	GL
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	Jan. 04	AQ
Lumos Pharma, Inc. Promotes Pisit Pitukcheewanont to Chief Medical Officer	Jan. 04	CI
Oppenheimer Trims Lumos Pharma Price Target to $16 From $17, Maintains Outperform Rating	Dec. 11	MT
Transcript : Lumos Pharma, Inc. - Special Call	Dec. 06
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	Nov. 21	GL
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	Nov. 21	AQ
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November	Nov. 20	GL
North American Morning Briefing : Stock Futures -2-	Nov. 13	DJ
Transcript : Lumos Pharma, Inc. - Special Call	Nov. 08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Summary

Filters